Having trouble accessing articles? Reset your cache.

Gene therapy data weigh on Ultragenyx shares

Ultragenyx shed more than $350 million in market cap on Wednesday as investors digested additional data from a Phase I/II trial of gene therapy DTX401 for glycogen storage disease and news that the company would add more patients to the trial to confirm the dose.

Data from

Read the full 465 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE